Picard Medical Reports 85% Revenue Growth, Eyes 2028 FDA Nod for Next-Gen Heart Device — Picard Medical, Inc.

Event summary

Picard Medical reported $1.2M in Q1 2026 revenue, up 85% YoY, with gross profit turning positive at 24% margin.
The company repaid $7.4M in senior secured debt and raised $5M in additional equity financing.
First-in-animal trials for the Emperor TAH, a next-gen fully implantable heart, were completed in May 2026.
NYSE American listing compliance plan due by June 7, 2026, following equity requirements notice.

The big picture

Picard Medical's strong financial performance in early 2026 reflects its strategic focus on debt reduction and gross margin expansion. The company's progress on the Emperor TAH positions it within the competitive landscape of advanced cardiac devices, where regulatory approvals and clinical adoption remain critical. With over 7,500 patients on the U.S. heart transplant waiting list, the demand for effective treatment options underscores the strategic importance of Picard Medical's technologies.

What we're watching

Regulatory Timeline: Whether Picard Medical can secure FDA approval for the Emperor TAH by 2028, given the unpredictable regulatory process.
Market Expansion: The pace at which Picard Medical can expand the eligible patient population following a potential FDA approval for bridge-to-candidacy patients.
Financial Sustainability: How the company's path to profitability will be affected by its ability to scale manufacturing capacity and reduce per-unit costs.